Literature DB >> 28176516

The current management of renal cell carcinoma.

Teele Kuusk1, Nikolaos Grivas1, Roderick de Bruijn1, Axel Bex2.   

Abstract

INTRODUCTION: Although the broad use of ultrasound and computed tomography (CT) has led to an early diagnosis of the disease, renal cell carcinoma (RCC) remains one of the most lethal urological cancers. The present review is based on the latest data published on RCC management. EVIDENCE ACQUISITION: A literature search was carried out searching recent publications from PubMed, MEDLINE, Embase up to December 2016 as well as European Association of Urology (EAU) and European Society of Medical Oncology (ESMO) guidelines. EVIDENCE SYNTHESIS: A narrative synthesis based on recent publications was undertaken. Current evidence regarding treatment strategies and guidelines is based on prospective randomized controlled trials and retrospective studies although the level of evidence for surgical management is generally lower than for systemic therapy.
CONCLUSIONS: This narrative review depicts a summary of the evidence base for treatment of RCC. Management of RCC is a rapidly evolving and changing field. As a consequence guidelines need regular updating and patients may benefit from centralization of care and multidisciplinary approach.

Entities:  

Mesh:

Year:  2017        PMID: 28176516     DOI: 10.23736/S0026-4806.17.05058-3

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  7 in total

1.  [Clinicopathologic features and prognostic analyses of locally recurrent renal cell carcinoma patients after initial surgery].

Authors:  Q Tang; R C Lin; L Yao; Z Zhang; H Hao; C J Zhang; L Cai; X S Li; Z S He; L Q Zhou
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

Review 2.  Tumor buster - where will the CAR-T cell therapy 'missile' go?

Authors:  Chunrun Qu; Hao Zhang; Hui Cao; Lanhua Tang; Haoyang Mo; Fangkun Liu; Liyang Zhang; Zhenjie Yi; Lifu Long; Luzhe Yan; Zeyu Wang; Nan Zhang; Peng Luo; Jian Zhang; Zaoqu Liu; Weijie Ye; Zhixiong Liu; Quan Cheng
Journal:  Mol Cancer       Date:  2022-10-19       Impact factor: 41.444

3.  Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.

Authors:  Qing Zhang; Kang Tian; Jinjing Xu; Haixu Zhang; Liantao Li; Qiang Fu; Dafei Chai; Huizhong Li; Junnian Zheng
Journal:  J Immunol Res       Date:  2017-12-20       Impact factor: 4.818

4.  A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility.

Authors:  Zhiqing Zhong; Hongyan Li; Hongzhen Zhong; Tianbiao Zhou; Weiji Xie; Zhijun Lin
Journal:  BMC Med Genet       Date:  2018-06-08       Impact factor: 2.103

5.  The correlation between affected renal function and affected renal residual volume: A retrospective outcome of laparoscopic nephron-sparing partial nephrectomy with segmental renal artery blocking-up for localized renal tumors.

Authors:  Fang-Min Chen; Rui-Jie Hu; Xi-Nan Jiang; Si-Wen Zhong; Shuai Tang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

6.  CARD10 promotes the progression of renal cell carcinoma by regulating the NF‑κB signaling pathway.

Authors:  Longfei Peng; Ke He; Zhangjun Cao; Liangkuan Bi; Dexin Yu; Qi Wang; Jinyou Wang
Journal:  Mol Med Rep       Date:  2019-11-21       Impact factor: 2.952

7.  C-reactive protein to albumin ratio predicts the outcome in renal cell carcinoma: A meta-analysis.

Authors:  Wei Zhou; Guang-Lin Zhang
Journal:  PLoS One       Date:  2019-10-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.